Table 2 Event rates in patients with cancer treated with certoparin or UFH
Pts with cancer at admission | Certoparin | UFH | OR (95%CI) | p-value* | ||
|---|---|---|---|---|---|---|
n/avail. | % | n/avail. | % | |||
Thromboembolic events | ||||||
Combined endpoint | 5/111 | 4.50 | 7/116 | 6.03 | 0.73 (0.23-2.39) | 0.6078 |
Proximal DVT | 5/111 | 4.50 | 5/114 | 4.39 | 1.03 (0.29-3.65) | 0.9656 |
Symptomatic non-fatal PE | 0/129 | 0 | 1/128 | 0.78 | - | - |
VTE related death | 0/131 | 0 | 1/132 | 0.76 | - | - |
Distal DVT | 10/101 | 9.90 | 7/106 | 6.60 | 1.55 (0.57-4.25) | 0.3908 |
Proximal or distal DVT | 12/101 | 11.88 | 9/106 | 8.49 | 1.45 (0.58-3.61) | 0.4213 |
Symptomatic DVT | 1/128 | 0.78 | 1/125 | 0.80 | 0.98 (0.06-15.78) | 0.9866 |
Death from any cause | 2/131 | 1.53 | 6/132 | 4.55 | 0.33 (0.06-1.64) | 0.1743 |